KR100853955B1 - 아크릴로일 디스타마이신 유도체 및 국소이성화효소 ⅰ 및ⅱ 억제제를 포함하는 약제학적 조성물 - Google Patents

아크릴로일 디스타마이신 유도체 및 국소이성화효소 ⅰ 및ⅱ 억제제를 포함하는 약제학적 조성물 Download PDF

Info

Publication number
KR100853955B1
KR100853955B1 KR1020027017440A KR20027017440A KR100853955B1 KR 100853955 B1 KR100853955 B1 KR 100853955B1 KR 1020027017440 A KR1020027017440 A KR 1020027017440A KR 20027017440 A KR20027017440 A KR 20027017440A KR 100853955 B1 KR100853955 B1 KR 100853955B1
Authority
KR
South Korea
Prior art keywords
amino
methyl
carbonyl
pyrrole
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020027017440A
Other languages
English (en)
Korean (ko)
Other versions
KR20030019448A (ko
Inventor
제로니마리아크리스티나로사
코치파올로
베리아이탈로
Original Assignee
네르비아노 메디칼 사이언시스 에스.알.엘.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 네르비아노 메디칼 사이언시스 에스.알.엘. filed Critical 네르비아노 메디칼 사이언시스 에스.알.엘.
Publication of KR20030019448A publication Critical patent/KR20030019448A/ko
Application granted granted Critical
Publication of KR100853955B1 publication Critical patent/KR100853955B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020027017440A 2000-06-23 2001-06-20 아크릴로일 디스타마이신 유도체 및 국소이성화효소 ⅰ 및ⅱ 억제제를 포함하는 약제학적 조성물 Expired - Fee Related KR100853955B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0015444.3 2000-06-23
GBGB0015444.3A GB0015444D0 (en) 2000-06-23 2000-06-23 Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and topoisomerase I and II inhibitors
PCT/EP2001/007059 WO2001097789A2 (en) 2000-06-23 2001-06-20 Pharmaceutical compositions comprising acryloyl distamycin derivatives and topoisomerase i and ii inhibitors

Publications (2)

Publication Number Publication Date
KR20030019448A KR20030019448A (ko) 2003-03-06
KR100853955B1 true KR100853955B1 (ko) 2008-08-25

Family

ID=9894285

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020027017440A Expired - Fee Related KR100853955B1 (ko) 2000-06-23 2001-06-20 아크릴로일 디스타마이신 유도체 및 국소이성화효소 ⅰ 및ⅱ 억제제를 포함하는 약제학적 조성물

Country Status (27)

Country Link
US (1) US20030162722A1 (enExample)
EP (1) EP1292290B1 (enExample)
JP (1) JP2003535890A (enExample)
KR (1) KR100853955B1 (enExample)
CN (1) CN1241573C (enExample)
AT (1) ATE323483T1 (enExample)
AU (2) AU2001278463B2 (enExample)
BR (1) BR0111813A (enExample)
CA (1) CA2411172C (enExample)
CZ (1) CZ20024155A3 (enExample)
DE (1) DE60118914T2 (enExample)
DK (1) DK1292290T3 (enExample)
EA (1) EA006684B1 (enExample)
EE (1) EE05319B1 (enExample)
ES (1) ES2261448T3 (enExample)
GB (1) GB0015444D0 (enExample)
HK (1) HK1054334B (enExample)
HU (1) HUP0301257A2 (enExample)
IL (1) IL153177A0 (enExample)
MX (1) MXPA02012163A (enExample)
NO (1) NO329783B1 (enExample)
NZ (1) NZ523000A (enExample)
PL (1) PL200503B1 (enExample)
PT (1) PT1292290E (enExample)
SK (1) SK287549B6 (enExample)
WO (1) WO2001097789A2 (enExample)
ZA (1) ZA200209834B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0015447D0 (en) * 2000-06-23 2000-08-16 Pharmacia & Upjohn Spa Combined therapy against tumors comprising substituted acryloyl derivates and alkylating agents
GB0015444D0 (en) * 2000-06-23 2000-08-16 Pharmacia & Upjohn Spa Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and topoisomerase I and II inhibitors
DK1461083T3 (da) * 2002-01-02 2006-07-10 Nerviano Medical Sciences Srl Kombineret terapi mod tumorer omfattende substitueret acryloyl distamycinderivater og proteinkinase- (serin/threoninkinase) inhibitorer
CN100438913C (zh) * 2004-11-22 2008-12-03 山东蓝金生物工程有限公司 一种抗癌药物组合物
MD36Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului ductal in situ neinvaziv al glandei mamare
MD23Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului lobular in situ neinvaziv al glandei mamare
MD24Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului neinvaziv al glandei mamare
MD35Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de apreciere a riscului dezvoltării carcinomului neinvaziv in situ al glandei mamare
AU2011274229A1 (en) 2010-07-02 2013-01-10 Angiochem Inc. Short and D-amino acid-containing polypeptides for therapeutic conjugates and uses thereof
CN109718228A (zh) * 2017-10-30 2019-05-07 沈阳药科大学 米托蒽醌的抗肿瘤淋巴转移作用及其药物制剂

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998004524A1 (en) * 1996-07-25 1998-02-05 Pharmacia & Upjohn S.P.A. Acryloyl substituted distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents
WO1998021202A1 (en) 1996-11-11 1998-05-22 Pharmacia & Upjohn S.P.A. Benzoheterocyclic distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9727524D0 (en) * 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Synergistic antitumor composition containing a biologically active ureido compound
GB9806692D0 (en) * 1998-03-27 1998-05-27 Pharmacia & Upjohn Spa Benzoheterocyclic distamycin derivatives, process for preparing them and their use as antitumour agents
GB0015444D0 (en) * 2000-06-23 2000-08-16 Pharmacia & Upjohn Spa Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and topoisomerase I and II inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998004524A1 (en) * 1996-07-25 1998-02-05 Pharmacia & Upjohn S.P.A. Acryloyl substituted distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents
WO1998021202A1 (en) 1996-11-11 1998-05-22 Pharmacia & Upjohn S.P.A. Benzoheterocyclic distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents

Also Published As

Publication number Publication date
NO20026078L (no) 2002-12-18
EA006684B1 (ru) 2006-02-24
HK1054334B (zh) 2006-09-22
CN1437474A (zh) 2003-08-20
SK18332002A3 (sk) 2003-07-01
CA2411172C (en) 2009-11-17
NZ523000A (en) 2005-12-23
GB0015444D0 (en) 2000-08-16
DE60118914T2 (de) 2006-12-21
WO2001097789A3 (en) 2002-05-16
EP1292290B1 (en) 2006-04-19
AU2001278463B2 (en) 2006-02-23
EE200200681A (et) 2004-06-15
KR20030019448A (ko) 2003-03-06
PL200503B1 (pl) 2009-01-30
CZ20024155A3 (cs) 2003-04-16
US20030162722A1 (en) 2003-08-28
PL360297A1 (en) 2004-09-06
EE05319B1 (et) 2010-08-16
HK1054334A1 (en) 2003-11-28
NO329783B1 (no) 2010-12-13
NO20026078D0 (no) 2002-12-18
CA2411172A1 (en) 2001-12-27
HUP0301257A2 (hu) 2003-08-28
PT1292290E (pt) 2006-08-31
IL153177A0 (en) 2003-06-24
SK287549B6 (sk) 2011-01-04
ATE323483T1 (de) 2006-05-15
EP1292290A2 (en) 2003-03-19
DE60118914D1 (de) 2006-05-24
ZA200209834B (en) 2003-12-04
AU7846301A (en) 2002-01-02
ES2261448T3 (es) 2006-11-16
BR0111813A (pt) 2003-05-20
MXPA02012163A (es) 2003-04-25
EA200300060A1 (ru) 2003-04-24
DK1292290T3 (da) 2006-07-10
CN1241573C (zh) 2006-02-15
WO2001097789A2 (en) 2001-12-27
JP2003535890A (ja) 2003-12-02

Similar Documents

Publication Publication Date Title
KR100853955B1 (ko) 아크릴로일 디스타마이신 유도체 및 국소이성화효소 ⅰ 및ⅱ 억제제를 포함하는 약제학적 조성물
AU2002221622B2 (en) Antitumor therapy comprising distamycin derivatives
AU2001278463A1 (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and topoisomerase i and ii inhibitors
KR100869037B1 (ko) 치환된 아크릴로일 디스타마이신 유도체 및 알킬화제를 포함하는 항종양 조성물
KR100861668B1 (ko) 치환된 아크릴로일 디스타마이신 유도체, 탁산 및/또는 항대사물질을 포함하는, 항종양 배합 치료제
AU2001281867A1 (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and alkylating agents
US20070249651A1 (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and topoisomerase I and II inhibitors
AU2001267553A1 (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives, taxanes and/or antimetabolites

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20110820

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20110820